USPTO Rule 56: Duty of Disclosure Explained for Patent Practitioners

What is USPTO Rule 56 (37 C.F.R. § 1.56) and Why Does It Matter? In the world of patent prosecution, few obligations carry as much weight – or as much risk – as the USPTO Rule 56 duty of disclosure. Whether you are a patent attorney, agent, inventor, or corporate IP manager, understanding this rule is not optional. It is a foundational requirement that governs every interaction with the United States Patent and Trademark Office (USPTO) during a patent application’s prosecution.

37 C.F.R. § 1.56, commonly referred to as USPTO Rule 56, establishes a strict duty of candor and good faith that all individuals associated with the filing and prosecution of a patent application owe to the USPTO. Failure to comply with this duty can result in consequences as severe as rendering an entire patent unenforceable – even if the patent would otherwise have been valid.

This article breaks down everything patent practitioners need to know about the USPTO Rule 56 duty of disclosure: who it applies to, what it covers, how it is enforced, and how to stay compliant in practice.

What is the USPTO Rule 56 (37 CFR §1.56) Duty of Disclosure?

At its core, USPTO Rule 56 imposes a legal and ethical obligation on all individuals substantively involved in a patent application to disclose to the USPTO any information they are aware of that is material to patentability.

The rule reads in part:

Who is Bound by the USPTO Rule 56 Duty of Disclosure?

One of the most important aspects of Rule 56 is understanding who it applies to. The duty is not limited to just the patent attorney or agent of record. It extends broadly to everyone “substantively involved” in the preparation or prosecution of the application.

Individuals Covered Under Rule 56

• Inventors – All named inventors are individually bound by the duty.
• Patent Attorneys and Agents – Legal representatives who prosecute the application on behalf of the applicant.
• Assignees and Corporate Applicants – Corporate entities and their IP departments when they are substantively involved in prosecution.
• Other Involved Parties – Any individual who is substantively involved in preparing or prosecuting the application, such as technical advisors, in-house counsel, or paralegals with substantive roles.

Important: Individuals who are not substantively involved – for example, administrative staff who merely transmit documents – are generally not bound by the duty. However, it is best practice to ensure that all parties connected to prosecution understand the scope of their obligations.

Also, Read: How IDS Management Can Protect Your Patent from Invalidity Challenges

What Information is “Material to Patentability”?

The term “material to patentability” is central to Rule 56, yet it is frequently misunderstood. The USPTO uses a “but for” materiality standard – information is material if the USPTO would not have allowed a claim had it been aware of the information.

Under the Current Materiality Standard, Information Is Material If:

• Prior Art: It is prior art that anticipates or renders obvious one or more claims in the application.
• Conflicting Information: It conflicts with or contradicts representations made to the USPTO.
• Claim Scope Concerns: It establishes that the claimed invention lacks novelty, non-obviousness, utility, enablement, or written description.
• Inconsistent Declarations: Sworn statements or declarations made during prosecution that are inconsistent with known facts.

Information That is NOT Required to Be Disclosed

• Cumulative information that is not more material than already-disclosed prior art.
• Information the applicant is unaware of at the time of prosecution.
• Information that is entirely unrelated to the subject matter of the claims.

Pro Tip for Practitioners: When in doubt, disclose. Erring on the side of disclosure is always safer than risking an inequitable conduct allegation later.

The Information Disclosure Statement (IDS): The Primary Vehicle for Compliance

The primary mechanism by which applicants comply with the USPTO Rule 56 duty of disclosure is the Information Disclosure Statement (IDS). An IDS is a formal submission to the USPTO that lists all prior art, publications, patents, and other information known to the applicant that may be material to patentability.

What an IDS Typically Includes

• U.S. Patents and Patent Applications
• Foreign Patents and Publications
• Non-Patent Literature (NPL): Journal articles, conference papers, technical reports, manuals, etc.
• Other Documents: Office actions from related foreign applications, search reports from international applications, and prior art cited by co-pending U.S. applications.

IDS Timing Rules: When Must an IDS Be Filed?

The timing of an IDS submission affects whether a fee is required and how the USPTO processes the submission:

Filing Window	Requirement
Before first Office Action on the merits	No fee required; examiner must consider all cited references
After first Office Action, before allowance	Requires fee OR statement that no information was cited in a prior art search or related application
After payment of issue fee	Requires petition, fee, and a statement of good cause
After patent issuance	Cannot be submitted to the issued patent; reexamination may be required

Best Practices for IDS Filing

• File Early and Often: Submit IDS as early as possible – ideally before or with the initial application filing.
• Search Foreign Counterparts: Review office actions and search reports from international counterparts and foreign national phase applications.
• Monitor Related Applications: Continuously monitor co-pending applications in the same family and disclose material prior art cited in those applications.
• Keep Records: Maintain thorough records of all prior art searches, information considered, and IDS submissions made.

Also, Read: Outsource IDS Filing: Why Law Firms Prefer It and the True Cost of DIY Filing

Inequitable Conduct: The Consequence of Violating Rule 56

Failure to comply with the USPTO Rule 56 duty of disclosure can give rise to a legal doctrine known as inequitable conduct – one of the most serious and damaging outcomes a patent holder can face.

What is Inequitable Conduct?

Inequitable conduct occurs when an individual with a duty of disclosure before the USPTO:

1. Withholds material information from the USPTO during prosecution, and
2. Does so with intent to deceive the USPTO.

Both elements – materiality and deceptive intent – must be proven for a successful inequitable conduct defense.

The Federal Circuit’s Therasense Standard (2011)

The landmark case Therasense, Inc. v. Becton, Dickinson and Co. (Fed. Cir. 2011) significantly tightened the standard for proving inequitable conduct by requiring:

• “But-For” Materiality: The withheld information must be such that the USPTO would not have allowed the claim if it had been aware of the information. (Exceptions apply for affirmative egregious misconduct.)
• Specific Intent to Deceive: The intent to deceive must be the single most reasonable inference drawn from the evidence – a showing of negligence or even gross negligence is insufficient.

Consequences of a Finding of Inequitable Conduct

• Unenforceability of the Entire Patent: Unlike invalidity, which may affect only certain claims, a finding of inequitable conduct renders the entire patent unenforceable, not just individual claims.
• Infectious Unenforceability: In some cases, inequitable conduct in one patent can infect related patents in the same family.
• Attorneys’ Fees: Under 35 U.S.C. § 285, a court may award attorneys’ fees to the prevailing party in “exceptional cases” – often triggered by inequitable conduct.
• Professional Discipline: Patent practitioners found to have committed inequitable conduct may face disciplinary proceedings before the USPTO Office of Enrollment and Discipline (OED), including suspension or disbarment from practice before the USPTO.

Common Scenarios That Trigger Rule 56 Issues

Understanding real-world scenarios where Rule 56 violations most commonly arise helps practitioners stay vigilant and proactive.

1. Failure to Disclose Known Prior Art

An inventor is aware of a competitor’s product or published paper that clearly anticipates or renders obvious the claimed invention but fails to bring it to the attention of their patent attorney. This is one of the most frequent sources of Rule 56 problems.

Prevention: Implement a robust prior art disclosure protocol at the outset of every patent matter. Require inventors to complete detailed prior art questionnaires and review technical literature.

2. Non-Disclosure of Related Foreign Applications

Applicants filing in multiple countries receive office actions and search reports from foreign patent offices. References cited in those foreign proceedings are often highly material and must be disclosed in the corresponding U.S. application.

Prevention: Establish a systematic process for forwarding international search reports and foreign office actions to U.S. counsel for IDS review.

3. Inconsistent Statements Across Applications

In patent families with multiple continuation or divisional applications, it is possible to make claim scope arguments or declarations in one application that are inconsistent with positions taken in another. These inconsistencies can trigger Rule 56 concerns.

Prevention: Maintain consistent prosecution histories across patent families. Review prior application file histories before making arguments about claim scope.

4. Failure to Disclose Co-Pending Application Art

Prior art cited by examiners in co-pending applications – even those from different inventors – may be material to a pending application’s claims.

Prevention: Establish cross-referencing protocols for co-pending applications, and regularly review examiner-cited art in related applications.

5. Inventor Concealment of Conflicting Test Data

In pharmaceutical and biotechnology patents, test data that contradicts the claimed efficacy or utility of an invention is highly material. Inventors who selectively present only favorable test results risk Rule 56 violations.

Prevention: Require full disclosure of all experimental results, including negative data, and assess materiality carefully before filing.

Also, Read: IDS vs. Prior Art Disclosure: Key Points for Patent Owners

USPTO Rule 56 in the Context of Continuation Applications and Patent Families

A particularly important and often overlooked aspect of the USPTO Rule 56 duty of disclosure involves its application to continuation applications and patent families.

Key Points for Patent Family Management

• The Duty Applies Independently to Each Application: Each continuation, continuation-in-part, or divisional application is treated as a separate application. The duty of disclosure applies fresh to each one.
• Art Cited in Parent Applications: Prior art cited during prosecution of a parent application is generally considered cumulative in a child application – but practitioners should review whether it is still material to the child’s specific claims.
• New Material Discovered After Parent Issuance: If new material prior art comes to light after a parent patent issues but while a continuation is pending, it must be disclosed in the continuation.
• Terminal Disclaimers and Family Art: When filing terminal disclaimers to overcome obviousness-type double patenting rejections, ensure that all material references from related applications are properly carried over.

Also, Read: How to Prepare an IDS: A Step-by-Step Guide for Patent Applicants

Rule 56 and Inter Partes Review (IPR) Proceedings

With the advent of Inter Partes Review (IPR) proceedings under the America Invents Act (AIA), Rule 56 compliance has taken on new importance. Prior art that surfaces during IPR proceedings is often the same art that, had it been known during prosecution, would have been material under Rule 56.

Key Considerations

• Pre-Filing Prior Art Searches: Conduct thorough prior art searches before filing to reduce the risk that highly relevant art will emerge in post-grant proceedings.
• IPR Petitions as Rule 56 Triggers: If material prior art is identified through an IPR petition filed against one patent in a family, consider whether that art must be disclosed in co-pending related applications.
• Reexamination as a Curative Tool: In some cases, if material art was not disclosed during prosecution, filing a reexamination request or pursuing reissue may help address the issue before it becomes a litigation defense.

Also, Read: IDS Filing Deadlines: How to Avoid Costly USPTO Penalties

Practical Compliance Checklist for Patent Practitioners

To stay compliant with the USPTO Rule 56 duty of disclosure, practitioners should implement a systematic compliance workflow. Use the following checklist as a starting point:

Before Filing

• Conduct a thorough prior art search and document all results
• Provide inventors with a prior art disclosure questionnaire
• Review all related foreign applications and their search results
• Assess all technical literature, conference papers, and prior products
• Identify all co-pending applications in the same family

During Prosecution

• Submit IDS promptly upon receipt of foreign search reports or office actions
• Review all examiner-cited art in related applications for cross-application materiality
• Monitor new publications and products for material prior art
• Ensure consistency of claim scope arguments across related applications
• Document all decisions regarding what to disclose and why

After Allowance

• Review any art identified after the Notice of Allowance but before issue fee payment
• If material art is identified after issue fee payment, assess whether supplemental examination or reexamination is appropriate
• For continuation applications, review cumulative vs. non-cumulative art from the parent

For Corporate IP Teams

• Implement inventor training programs on Rule 56 obligations
• Establish protocols for routing foreign office actions to U.S. prosecution counsel
• Create standardized IDS workflows for high-volume prosecution departments
• Conduct periodic audits of patent family prosecution histories

Rule 56 vs. Patent Prosecution Highway (PPH): Leveraging Global Prosecution

Many patent practitioners use the Patent Prosecution Highway (PPH) to accelerate U.S. prosecution based on favorable examination results in other countries. However, PPH use creates an important Rule 56 intersection:

• References cited by foreign examiners during the PPH examination are material to patentability and must be disclosed via IDS in the U.S. application.
• Office actions received during PPH-accelerated examination in the U.S. must be reviewed for art that may be material to co-pending applications.

Practitioners leveraging PPH should build automatic IDS review steps into their PPH workflows to ensure compliance.

Also, Read: What is an Information Disclosure Statement (IDS) and Why Does It Matter for Your Patent?

Supplemental Examination: A Post-Grant Compliance Tool

The AIA introduced supplemental examination under 35 U.S.C. § 257 as a mechanism that allows patent owners to request that the USPTO consider, reconsider, or correct information believed to be relevant to the patent. A significant benefit of supplemental examination is that it can immunize a patent against inequitable conduct allegations related to information submitted during the supplemental examination proceeding.

When to Consider Supplemental Examination

• When material information was not submitted during original prosecution due to oversight or lack of knowledge.
• When a patent is expected to be litigated and the patentee wants to shore up its prosecution history.
• When new prior art surfaces after issuance that may raise inequitable conduct concerns.

Note: Supplemental examination does not cure inequitable conduct that is already the subject of a pending litigation claim – only pre-litigation supplemental examination provides the immunity benefit.

The Ethical Dimension: USPTO Rule 56 (37 CFR §1.56) and Professional Responsibility

Beyond the legal and business consequences, USPTO Rule 56 has a profound ethical dimension for patent practitioners. The duty of disclosure is fundamentally a duty of honesty – to the USPTO, to the public, and to the integrity of the patent system itself.

USPTO Code of Professional Responsibility

The USPTO’s rules of professional conduct (37 C.F.R. Part 11) require patent practitioners to maintain the highest standards of candor and integrity. Violations of Rule 56 can lead to:

• Investigation by the OED (Office of Enrollment and Discipline)
• Formal disciplinary proceedings
• Suspension or exclusion from practice before the USPTO
• Referral to state bar authorities for attorneys who are also licensed to practice law

Patent practitioners must understand that they are officers of the USPTO, and their obligation of candor runs not only to their client but also to the institution itself.

Frequently Asked Questions (FAQ): USPTO Rule 56 (37 CFR §1.56) Duty of Disclosure

Q: Does the duty of disclosure apply to information the applicant later discovers to be material? Yes. If material information comes to light after the application is filed but before it issues, the applicant is obligated to disclose it. The duty is ongoing throughout prosecution.

Q: What happens if I disclose too much – can irrelevant disclosures hurt my application? Technically, disclosing non-material information is not penalized. However, excessive and undifferentiated disclosures can slow prosecution and may cause important references to be overlooked. Quality of disclosure matters as much as quantity.

Q: Is the duty of disclosure the same in continuation applications as in the parent? Each application carries its own independent duty of disclosure. Art that was cumulative in the parent may still be relevant in the continuation if the claims have materially changed.

Q: Can inequitable conduct be cured after the patent issues? Supplemental examination can provide immunity from inequitable conduct allegations for information submitted during the proceeding, but it cannot cure inequitable conduct that is already the subject of pending litigation.

Q: What is the “reasonable examiner” standard in the context of materiality? The “reasonable examiner” standard – used prior to the Therasense decision – asked whether a reasonable examiner would have considered the information important in deciding whether to allow the application. The current “but for” standard under Therasense is stricter and requires that the withheld information would have actually changed the outcome of prosecution.

Compliance is Not Optional – It is Foundational

The USPTO Rule 56 duty of disclosure is one of the most consequential rules in all of U.S. patent law. For patent practitioners, it is not merely a procedural box to check – it is a foundational ethical and legal obligation that shapes every stage of patent prosecution.

Complying with Rule 56 requires:

• Proactive prior art identification from the earliest stages of patent strategy
• Rigorous IDS filing protocols that account for foreign prosecution, co-pending applications, and ongoing monitoring
• Consistency and candor in all representations made to the USPTO
• Continuous training for inventors, in-house counsel, and outside practitioners
• A culture of disclosure within IP departments and prosecution teams

At Teak IP Services, we help patent applicants and practitioners navigate the complex requirements of U.S. patent prosecution – including full compliance with the USPTO Rule 56 duty of disclosure. Our experienced team provides comprehensive patent prosecution support, IDS management services, and strategic IP counsel to protect your innovations and the integrity of your patent portfolio.

Learn More About IDS Preparation & Filing Services